Integrative landscape of dysregulated signaling pathways of clinically distinct pancreatic cancer subtypes.

ABSTRACT: Despite modern therapeutic advances, the survival prospects of pancreatic cancer patients have remained poor. Besides being highly metastatic, pancreatic cancer is challenging to treat because it is caused by a heterogeneous array of somatic mutations that impact a variety of signaling pathways and cellular regulatory systems. Here we use publicly available transcriptomic, copy number alteration and mutation profiling datasets from pancreatic cancer patients together with data on disease outcomes to show that the three major pancreatic cancer subtypes each display distinctive aberrations in cell signaling and metabolic pathways. Importantly, patients afflicted with these different pancreatic cancer subtypes also exhibit distinctive survival profiles. Within these patients, we find that dys

SUBMITTER: Sinkala M 

PROVIDER: S-EPMC6044387 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature